Loss of nuclear myosin 1 causes hemostatic defects and immune dysregulation [0.03%]
核肌动蛋白肌球蛋白1丢失导致凝血缺陷和免疫调节异常
Tomas Venit,Samira Khalaji,Valentina Fambri et al.
Tomas Venit et al.
Not available.
Single-cell profiling of CD19-directed CAR-T cell phenotypes and immune system dynamics in pediatric B-cell acute lymphoblastic leukemia [0.03%]
CD19导向的CAR-T细胞表型和儿科B淋巴母细胞白血病免疫系统动力学的单细胞谱系追踪分析
Aleksandra Oszer,Bartlomiej Pawlik,Natalia Cwilichowska-Puslecka et al.
Aleksandra Oszer et al.
Not available.
JAK inhibitor selection in challenging scenarios of myelofibrosis: a review [0.03%]
我的纤维板病艰难情况下的JAK抑制剂选择：综述
Pankit Vachhani,Ruben Mesa,John Mascarenhas et al.
Pankit Vachhani et al.
Myelofibrosis is a progressive myeloproliferative neoplasm characterized by dysregulated Janus kinase (JAK)/signal transducer and activator of transcription signaling. Common clinical manifestations include constitutional symptoms, splenome...
Decitabine plus all- trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial [0.03%]
地西他滨联合全反式维甲酸治疗伴原始细胞增多的骨髓增生异常综合征的多中心随机对照研究
Xinping Zhou,Yanjuan Lin,Yan Gao et al.
Xinping Zhou et al.
Despite standard treatment with hypomethylating agents, the prognosis of patients with higher-risk myelodysplastic syndrome (MDS) remains poor. All-trans retinoic acid (ATRA) has demonstrated promising efficacy in unfit patients with acute ...
Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication [0.03%]
Quizartinib联合大剂量阿糖胞苷和米托蒽醌治疗FLT3内部串联重复阳性复发/难治性急性髓系白血病的多中心一线随机II期临床试验
Sonia Jaramillo,Johannes Krisam,Lucian Le Cornet et al.
Sonia Jaramillo et al.
Not available.
Deletion mutations of the ABL1 gene in Philadelphia chromosome-positive acute lymphoblastic leukemia: high prevalence with limited clinical impact [0.03%]
费城染色体阳性急性淋巴细胞白血病ABL1基因缺失突变的高检出率及其有限的临床意义
Hirofumi Takano,Shinsuke Takagi,Kana Kato et al.
Hirofumi Takano et al.
Not available.
Novel cryptic ADAMTS13 epitopes uncover a distinct open ADAMTS13 conformation in immune-mediated TTP [0.03%]
新的隐蔽ADAMTS13抗原表位揭示了免疫介导的TTP中独特的开放ADAMTS13构象
Quintijn Bonnez,Febe Boudry,Laure De Waele et al.
Quintijn Bonnez et al.
Open ADAMTS13 conformation is gaining clinical interest as a biomarker for diagnosing immune-mediated thrombotic thrombocytopenic purpura (iTTP) and monitoring remission patients for increased relapse risks. Yet, little is known on how open...
A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study [0.03%]
预测急性早幼粒细胞白血病患者发生致死性血栓/缺血事件的评分系统：PETHEMA/PALG研究
Rebeca Rodríguez-Veiga,Cristina Gil,Marta Sobas et al.
Rebeca Rodríguez-Veiga et al.
Acute promyelocytic leukemia (APL) is a highly curable leukemia characterized by life-threatening coagulopathy leading to hemorrhagic and thrombo-ischemic events. We analyzed the incidence, outcomes and risk-factors of thromboischemic event...
Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis [0.03%]
emicizumab预防获得性血友病A患者的突破性出血的凝血酶生成预测价值
Fabius J Pelzer,Ella I Ertekin,Olga Oleshko et al.
Fabius J Pelzer et al.
Acquired hemophilia A (AHA) is a serious bleeding disorder due to neutralizing autoantibodies against factor VIII (FVIII). Emicizumab mimics the activity of FVIIIa restoring thrombin generation. It was shown to protect patients with AHA fro...
Francesco Zorutti,Rebecca Sembenico,Antonio Pierini
Francesco Zorutti
Not available.